Company Profile
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company develops drugs for neurological and oncological diseases in Taiwan and the rest of Asia. The company offers Naldebain (LT-1001), an analgesic injection for postoperative pain. It also develops LT3001, which has completed Phase 2b clinical trials for the treatment of acute ischemic stroke.
Its portfolio also includes LT6001, which is in pre-clinical trials for the treatment of neurological disorders, and CS028, which is in the pre-clinical stage for the treatment of solid tumors. Additionally, it engages in the investment, new drug development consulting, and service and transfer of techniques activities.
Formerly known as SunTen Phytotech Co., Ltd., the company rebranded as Lumosa Therapeutics Co., Ltd. in June 2014. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.